Renaissance Capital logo

Immune Design Priced, Nasdaq: IMDZ

Early-stage biotech developing immunotherapy oncology treatments.

Industry: Health Care

First Day Return: +0.4%

Early-stage biotech developing immunotherapy oncology treatments.

Immune Design (IMDZ) Performance

Created with Highcharts 10.3.2Chart context menuIMDZ vs. IPO Index (IPOUSA)20152016201720182019202020212022202320242025-100%0%+ 100%+ 200%+ 300%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index